- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
- 20-F Annual report (foreign)
- 2.1 Description of Securities
- 4.17 Amendment No. 1 to Pre-funded Warrant Dated April 26, 2023 Between NLS Pharmaceutics LTD. and the Pre-funded Warrant Holders Named Therein
- 4.18 License Agreement by and Between NLS Pharmaceutics LTD. and Aexon Labs Inc., Dated March 19, 2024
- 12.1 Certification
- 12.2 Certification
- 13.1 Certification
- 13.2 Certification
- 15.1 Consent of Pricewaterhousecoopers Ag.
- 16.1 Letter of Pricewaterhousecoopers Ag Dated May 15, 2024
- 97.1 Clawback Policy
- Download Excel data file
- View Excel data file
Exhibit 16.1
May 15, 2024
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Commissioners:
We have read the statements made by NLS Pharmaceutics Ltd. (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 16F of its Annual Report on Form 20-F of NLS Pharmaceutics Ltd. dated May 15, 2024. We agree with the statements concerning our Firm contained therein.
Very truly yours,
/s/ PricewaterhouseCoopers AG
Zurich, Switzerland
Attachment
PricewaterhouseCoopers AG, Birchstrasse 160, Postfach, 8050 Zürich
T: +41 58 792 44 00, F: +41 58 792 44 10, www.pwc.ch
PricewaterhouseCoopers AG is a member of a global network of companies that are legally independent of one another.